DMS 0947 Exploratory Study of the Modulation of the Immune System by Vascular Endothelial Growth Factor (VEGF) Blockade in Patients With Glioblastoma Multiforme (GBM)
Phase of Trial: Phase 0
Latest Information Update: 30 May 2018
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Pharmacodynamics
- 24 May 2018 Status changed from active, no longer recruiting to completed.
- 18 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
- 02 Mar 2016 Planned End Date changed from 1 Jan 2016 to 1 Jul 2016, as reported by ClinicalTrials.gov.